Transcranial Doppler (TCD) for Subarachnoid Haemorrhage—Early Vasospasm Alerts for Neurocritical Care

26 September 2025

Enhance neurocritical care with MedTech Edge in Australia, offering advanced Transcranial Doppler platforms for timely vasospasm detection in SAH.

Subarachnoid haemorrhage (SAH) represents one of the most severe neurological emergencies, often caused by a ruptured cerebral aneurysm. Among its complications, delayed cerebral ischaemia from vasospasm poses the greatest threat to survival and long-term recovery. Transcranial Doppler has emerged as a reliable, non-invasive tool that allows real-time monitoring of cerebral circulation, enabling early detection of flow changes and timely intervention to prevent irreversible damage.

Role of Transcranial Doppler (TCD)

TCD is an ultrasound-based technique that measures blood flow velocity within the cerebral arteries. Unlike static imaging modalities, it allows dynamic assessment and can be performed repeatedly at the bedside, making it invaluable in intensive care environments.

At MedTech Edge, we offer tailored TCD solutions designed to provide clinicians with clarity, speed, and diagnostic confidence:

• Dolphin Max: Provides high-resolution imaging for detailed analysis of cerebral haemodynamics, supporting precise interpretation of subtle flow changes.

• Dolphin 4D: Delivers four-dimensional imaging for a comprehensive evaluation of intracranial blood flow, offering deeper insights into vascular dynamics.

• Dolphin IQ: Integrates intelligent algorithms that enhance diagnostic accuracy through automated data interpretation, streamlining clinician decision-making.

• Dolphin XF-Robot: Utilises robotic precision to standardise examinations, minimising operator variability and ensuring consistent, reproducible results that improve patient outcomes.

These advanced platforms empower clinicians with tools to detect, monitor, and respond rapidly to vasospasm risk in SAH patients.

Subarachnoid Haemorrhage: Vasospasm as a Critical Complication

While immediate mortality from SAH is a primary concern, survivors face the ongoing risk of cerebral vasospasm. This delayed narrowing of arteries reduces cerebral blood flow and can lead to secondary ischaemic injury. Detecting vasospasm before infarction occurs is essential to improving survival rates and reducing disability.

Detecting Early Vasospasm with TCD

Transcranial Doppler provides clinicians with an immediate, bedside tool to identify vasospasm before clinical deterioration occurs. This early detection ensures that treatment can begin at the most critical window, reducing the chance of permanent neurological damage. By delivering continuous, real-time data, TCD allows healthcare teams to make evidence-based decisions with greater confidence.

In the review “Transcranial Doppler Monitoring in Subarachnoid Hemorrhage” (J Neurosonol Neuroimag, 2022; 14[1]: 1–9), Park et al. emphasize that TCD enables real-time, bedside detection of cerebral vasospasm and serial monitoring of treatment efficacy in SAH patients. This evidence underscores TCD’s value as a non-invasive, dynamic monitoring tool that enhances timely intervention in neurocritical care settings following subarachnoid haemorrhage.

TCD in Daily Neurocritical Care

The integration of TCD into routine neurocritical workflows has transformed SAH monitoring. Its role goes beyond vasospasm detection and contributes to comprehensive patient care:

• Continuous, real-time cerebral flow assessment
• Non-invasive, bedside application
• Guidance for therapy adjustments
• Objective data to support decision-making
• Improved survival and recovery rates

MedTech Edge: Advancing Neurocritical Care

At MedTech Edge, we are committed to delivering innovative Transcranial Doppler solutions that exceed industry standards and integrate seamlessly into routine clinical practice. By enabling early vasospasm detection in subarachnoid haemorrhage, our products empower neurocritical care teams and reflect our vision to provide clinicians with technologies that genuinely improve patient outcomes.

Take the next step in advancing patient care. Contact us at MedTech Edge today to learn how our TCD solutions can support your neurocritical care team.

Optimized by: Netwizard SEO